Validation d’une méthode Elisa pour la recherche de l’antigène aspergillaire galactomannane en vue de l’accréditation

Kauffmann‐Lacroix, C.; Arvier, Matthieu; Charron, Maureen J.; Rodier, M.; Vassault, Anne

doi:10.1016/j.mycmed.2012.12.048

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this setting, detection of circulating surrogate biomarkers of IA such as BDG or galacatomannan (GM) may be useful not only for diagnosing disease but also for assessing the effectiveness of therapy [48]. This has been demonstrated for GM antigenemia, since declining levels of GM have been found in patients responding to antifungal treatment while rising GM antigenemia has been associated with treatment failure [49,50]. The role of serum BDG testing in the therapeutic monitoring of patients with IA was first established by Pazos and colleagues in a retrospective evaluation of 40 high risk, neutropenic adult patients [51].…”

Section: (1→3)-β-d-glucan (Bdg) In Serummentioning

confidence: 99%

Translational Development and Application of (1→3)-β-d-Glucan for Diagnosis and Therapeutic Monitoring of Invasive Mycoses

McCarthy

Petraitienė

Walsh

2017

IJMS

View full text Add to dashboard Cite

Early diagnosis and prompt initiation of appropriate antimicrobial therapy are crucial steps in the management of patients with invasive fungal infections. However, the diagnosis of invasive mycoses remains a major challenge in clinical practice, because presenting symptoms may be subtle and non-invasive diagnostic assays often lack sensitivity and specificity. Diagnosis is often expressed on a scale of probability (proven, probable and possible) based on a constellation of imaging findings, microbiological tools and histopathology, as there is no stand-alone assay for diagnosis. Recent data suggest that the carbohydrate biomarker (1→3)-β-d-glucan may be useful in both the diagnosis and therapeutic monitoring of invasive fungal infections due to some yeasts, molds, and dimorphic fungi. In this paper, we review recent advances in the use of (1→3)-β-d-glucan to monitor clinical response to antifungal therapy and explore how this assay may be used in the future.

show abstract

Section: (1→3)-β-d-glucan (Bdg) In Serummentioning

confidence: 99%